What happened: The UK medicines regulator has paused a clinical trial of puberty blockers, suggesting the minimum age for participants should be raised to 14. The decision follows concerns about the suitability of the current age limit.
Why it matters:
- The pause affects young people undergoing treatment related to gender identity development.
- It highlights regulatory caution in medical trials involving minors and hormone treatments.
MNN Take: Regulators aim to ensure clinical trials are conducted safely, especially when treatments involve children and adolescents, by reviewing age limits and trial protocols.
Sources: BBC UK